{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:30:33Z","timestamp":1794011433839,"version":"4.8.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02765-7","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T10:06:45Z","timestamp":1780308405000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dual epitope anti-LILRB4 synthetic T-cell receptor and antigen receptor (STAR)-T-cell therapy for relapsed\/refractory acute myeloid leukemia"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6625-9523","authenticated-orcid":false,"given":"Meng","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuying","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0956-3654","authenticated-orcid":false,"given":"Xin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-6643","authenticated-orcid":false,"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiasheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"2765_CR1","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1586\/17474086.2014.958464","volume":"7","author":"A Isidori","year":"2014","unstructured":"Isidori, A. et al. The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment. Expert Rev. Hematol. 7, 807\u2013818 (2014).","journal-title":"Expert Rev. Hematol."},{"key":"2765_CR2","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/ajh.25620","volume":"94","author":"M Molica","year":"2019","unstructured":"Molica, M., Breccia, M., Foa, R., Jabbour, E. & Kadia, T. M. Maintenance therapy in AML: the past, the present and the future. Am. J. Hematol. 94, 1254\u20131265 (2019).","journal-title":"Am. J. Hematol."},{"key":"2765_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","volume":"20","author":"D Vetrie","year":"2020","unstructured":"Vetrie, D., Helgason, G. V. & Copland, M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat. Rev. Cancer 20, 158\u2013173 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"2765_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41375-023-02076-8","volume":"38","author":"C Cerella","year":"2024","unstructured":"Cerella, C. et al. ATP1A1\/BCL2L1 predicts the response of myelomonocytic and monocytic acute myeloid leukemia to cardiac glycosides. Leukemia 38, 67\u201381 (2024).","journal-title":"Leukemia"},{"key":"2765_CR5","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. N. Engl. J. Med. 373, 1136\u20131152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2765_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11864-017-0456-2","volume":"18","author":"P Bose","year":"2017","unstructured":"Bose, P., Vachhani, P. & Cortes, J. E. Treatment of relapsed\/refractory acute myeloid leukemia. Curr. Treat. Options Oncol. 18, 17 (2017).","journal-title":"Curr. Treat. Options Oncol."},{"key":"2765_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2765_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2765_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50485-9","volume":"15","author":"S Zuo","year":"2024","unstructured":"Zuo, S. et al. C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial. Nat. Commun. 15, 6155 (2024).","journal-title":"Nat. Commun."},{"key":"2765_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/BS9.0000000000000109","volume":"4","author":"T Yang","year":"2022","unstructured":"Yang, T. et al. LILRB4, an immune checkpoint on myeloid cells. Blood Sci. 4, 49\u201356 (2022).","journal-title":"Blood Sci."},{"key":"2765_CR11","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/cyto.b.21952","volume":"100","author":"HRO Churchill","year":"2021","unstructured":"Churchill, H. R. O. et al. Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation. Cytom. B Clin. Cytom. 100, 476\u2013487 (2021).","journal-title":"Cytom. B Clin. Cytom."},{"key":"2765_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cyto.b.21050","volume":"84","author":"H Dobrowolska","year":"2013","unstructured":"Dobrowolska, H. et al. Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation. Cytom. B Clin. Cytom. 84, 21\u201329 (2013).","journal-title":"Cytom. B Clin. Cytom."},{"key":"2765_CR13","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","volume":"26","author":"S John","year":"2018","unstructured":"John, S. et al. A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML. Mol. Ther. 26, 2487\u20132495 (2018).","journal-title":"Mol. Ther."},{"key":"2765_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","volume":"562","author":"M Deng","year":"2018","unstructured":"Deng, M. et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature 562, 605\u2013609 (2018).","journal-title":"Nature"},{"key":"2765_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1158\/0008-5472.BCD-19-0041","volume":"1","author":"E Waanders","year":"2020","unstructured":"Waanders, E. et al. Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia. Blood Cancer Discov. 1, 96\u2013111 (2020).","journal-title":"Blood Cancer Discov."},{"key":"2765_CR16","first-page":"3149","volume":"12","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. LILRB4, from the immune system to the disease target. Am. J. Transl. Res. 12, 3149\u20133166 (2020).","journal-title":"Am. J. Transl. Res."},{"key":"2765_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100126","volume":"2","author":"A Aribi","year":"2025","unstructured":"Aribi, A. et al. A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia. Blood Neoplasia 2, 100126 (2025).","journal-title":"Blood Neoplasia"},{"key":"2765_CR18","doi-asserted-by":"publisher","unstructured":"Liu, Y. et al. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Sci. Transl. Med. 13, https:\/\/doi.org\/10.1126\/scitranslmed.abb5191 (2021).","DOI":"10.1126\/scitranslmed.abb5191"},{"key":"2765_CR19","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/ajh.26586","volume":"97","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. A novel adoptive synthetic TCR and antigen receptor (STAR) T-cell therapy for B-Cell acute lymphoblastic leukemia. Am. J. Hematol. 97, 992\u20131004 (2022).","journal-title":"Am. J. Hematol."},{"key":"2765_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114949","volume":"43","author":"D Huang","year":"2024","unstructured":"Huang, D. et al. TCR-mimicking STAR conveys superior sensitivity over CAR in targeting tumors with low-density neoantigens. Cell Rep. 43, 114949 (2024).","journal-title":"Cell Rep."},{"key":"2765_CR21","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1158\/2326-6066.CIR-19-0036","volume":"7","author":"X Gui","year":"2019","unstructured":"Gui, X. et al. Disrupting LILRB4\/APOE interaction by an efficacious humanized antibody reverses T-cell suppression and blocks AML development. Cancer Immunol. Res. 7, 1244\u20131257 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"2765_CR22","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1158\/2326-6066.CIR-21-0240","volume":"9","author":"KJ Paavola","year":"2021","unstructured":"Paavola, K. J. et al. The fibronectin-ILT3 interaction functions as a stromal checkpoint that suppresses myeloid cells. Cancer Immunol. Res. 9, 1283\u20131297 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"2765_CR23","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.3324\/haematol.2023.284228","volume":"109","author":"L Gong","year":"2024","unstructured":"Gong, L. et al. LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma. Haematologica 109, 3650\u20133669 (2024).","journal-title":"Haematologica"},{"key":"2765_CR24","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.ymthe.2020.06.022","volume":"28","author":"C Sommer","year":"2020","unstructured":"Sommer, C. et al. Allogeneic FLT3 CAR T cells with an off-switch exhibit potent activity against AML and can be depleted to expedite bone marrow recovery. Mol. Ther. 28, 2237\u20132251 (2020).","journal-title":"Mol. Ther."},{"key":"2765_CR25","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1002\/ijc.70146","volume":"158","author":"Y Liu","year":"2026","unstructured":"Liu, Y. et al. Integrated scFv identification and CAR T cell generation for AML targeting in vivo. Int J. Cancer 158, 994\u20131007 (2026).","journal-title":"Int J. Cancer"},{"key":"2765_CR26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13046-024-03110-y","volume":"43","author":"H Wang","year":"2024","unstructured":"Wang, H. et al. LILRB4 on multiple myeloma cells promotes bone lesion by p-SHP2\/NF-kappaB\/RELT signal pathway. J. Exp. Clin. Cancer Res. 43, 183 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2765_CR27","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","volume":"35","author":"N Daver","year":"2021","unstructured":"Daver, N., Alotaibi, A. S., Bucklein, V. & Subklewe, M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia 35, 1843\u20131863 (2021).","journal-title":"Leukemia"},{"key":"2765_CR28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s12185-024-03809-w","volume":"120","author":"S Saito","year":"2024","unstructured":"Saito, S. & Nakazawa, Y. CAR-T cell therapy in AML: recent progress and future perspectives. Int J. Hematol. 120, 455\u2013466 (2024).","journal-title":"Int J. Hematol."},{"key":"2765_CR29","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood.2024024063","volume":"145","author":"S Haubner","year":"2025","unstructured":"Haubner, S., Subklewe, M. & Sadelain, M. Honing CAR T cells to tackle acute myeloid leukemia. Blood 145, 1113\u20131125 (2025).","journal-title":"Blood"},{"key":"2765_CR30","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"MY Kim","year":"2018","unstructured":"Kim, M. Y. et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell 173, 1439\u20131453.e1419 (2018).","journal-title":"Cell"},{"key":"2765_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29668-9","volume":"13","author":"M Sugita","year":"2022","unstructured":"Sugita, M. et al. Allogeneic TCRalphabeta deficient CAR T-cells targeting CD123 in acute myeloid leukemia. Nat. Commun. 13, 2227 (2022).","journal-title":"Nat. Commun."},{"key":"2765_CR32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","volume":"15","author":"X Jin","year":"2022","unstructured":"Jin, X. et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia. J. Hematol. Oncol. 15, 88 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2765_CR33","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1182\/blood-2020-140907","volume":"136","author":"C Tong","year":"2020","unstructured":"Tong, C. et al. Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma. Blood 136, 1632\u20131644 (2020).","journal-title":"Blood"},{"key":"2765_CR34","doi-asserted-by":"publisher","unstructured":"Yu, L. et al. Converting TCR-based chimeric antigen receptor STAR into dual-specific targeting receptor for cancer immunotherapy. Mol. Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2025.02.001 (2025).","DOI":"10.1016\/j.ymthe.2025.02.001"},{"key":"2765_CR35","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"2765_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101826","volume":"5","author":"V Rubino","year":"2024","unstructured":"Rubino, V. et al. IL-21\/IL-21R signaling renders acute myeloid leukemia stem cells more susceptible to cytarabine treatment and CAR T cell therapy. Cell Rep. Med. 5, 101826 (2024).","journal-title":"Cell Rep. Med."},{"key":"2765_CR37","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41423-019-0321-2","volume":"17","author":"Z Li","year":"2020","unstructured":"Li, Z. et al. LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells. Cell Mol. Immunol. 17, 272\u2013282 (2020).","journal-title":"Cell Mol. Immunol."},{"key":"2765_CR38","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1038\/s41591-024-03271-5","volume":"30","author":"AS Bhagwat","year":"2024","unstructured":"Bhagwat, A. S. et al. Cytokine-mediated CAR T therapy resistance in AML. Nat. Med. 30, 3697\u20133708 (2024).","journal-title":"Nat. Med."},{"key":"2765_CR39","doi-asserted-by":"publisher","unstructured":"Sharma, N., Atolagbe, O. T., Ge, Z. & Allison, J. P. LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. J. Exp. Med. 218, https:\/\/doi.org\/10.1084\/jem.20201811 (2021).","DOI":"10.1084\/jem.20201811"},{"key":"2765_CR40","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329\u2013337 e324 (2019).","journal-title":"Cell Syst."},{"key":"2765_CR41","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587.e3529 (2021).","journal-title":"Cell"},{"key":"2765_CR42","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"2765_CR43","doi-asserted-by":"publisher","first-page":"D853","DOI":"10.1093\/nar\/gkac816","volume":"51","author":"S Jiang","year":"2023","unstructured":"Jiang, S. et al. Cell Taxonomy: a curated repository of cell types with multifaceted characterization. Nucleic Acids Res. 51, D853\u2013D860 (2023).","journal-title":"Nucleic Acids Res."},{"key":"2765_CR44","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41596-024-01045-4","volume":"20","author":"S Jin","year":"2025","unstructured":"Jin, S., Plikus, M. V. & Nie, Q. CellChat for systematic analysis of cell-cell communication from single-cell transcriptomics. Nat. Protoc. 20, 180\u2013219 (2025).","journal-title":"Nat. Protoc."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02765-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02765-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02765-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:03:05Z","timestamp":1780311785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02765-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2765"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02765-7","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.L., X.Q.Z., and X.L. have patents related to LILRB4 STARs. L.L. and H.L.Z. are employees of Bristar Immunotech Limited Co., Ltd. The remaining authors declare that they have no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The animal studies were reviewed and approved by the Institutional Animal Care and Use Committee of Peking University Health Science Center (CIBR-IACUC-042), and the clinical trial was approved by the Ethics Committee of Peking University People\u2019s Hospital (Ethics Approval Number: 2022PHD007).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"203"}}